Brought to you by 
Kite Pharma nets $204mm through first post-IPO follow-on
05 Jan 2015
Executive Summary
Just six months after raising $118.6mm through its initial public offering, cancer immunotherapeutics firm Kite Pharma Inc. netted $204mm through a follow-on public offering. The company sold 4mm shares (including the overallotment) at $54, and will use the proceeds to advance its eACT engineered autologous T-cell therapy candidates (chimeric antigen receptor (CAR) and T-cell receptors (TCR)) through clinical trials for various blood and solid cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite Pharma nets $204mm through first post-IPO follow-on
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice